Hans Schambye, Galecto CEO
October 8, 2020 07:15 AM EDT
Financing

Not two weeks af­ter clos­ing a Se­ries D round, Galec­to files for $100M IPO

Max Gelman

Senior Editor

Galec­to Biotech is piv­ot­ing to the pub­lic mar­ket less than two weeks af­ter com­plet­ing a $64 mil­lion Se­ries D round.

The Copen­hagen-based com­pa­ny filed its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times